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Abstract
Understanding the molecular mechanism of signalling in the important super-family of G-protein-coupled receptors
(GPCRs) is causally related to questions of how and where these receptors can be activated or inhibited. In this context, it is
of great interest to unravel the common molecular features of GPCRs as well as those related to an active or inactive state or
to subtype specific G-protein coupling. In our underlying chemogenomics study, we analyse for the first time the statistical
link between the properties of G-protein-coupled receptors and GPCR ligands. The technique of mutual information (MI) is
able to reveal statistical inter-dependence between variations in amino acid residues on the one hand and variations in
ligand molecular descriptors on the other. Although this MI analysis uses novel information that differs from the results of
known site-directed mutagenesis studies or published GPCR crystal structures, the method is capable of identifying the
well-known common ligand binding region of GPCRs between the upper part of the seven transmembrane helices and the
second extracellular loop. The analysis shows amino acid positions that are sensitive to either stimulating (agonistic) or
inhibitory (antagonistic) ligand effects or both. It appears that amino acid positions for antagonistic and agonistic effects are
both concentrated around the extracellular region, but selective agonistic effects are cumulated between transmembrane
helices (TMHs) 2, 3, and ECL2, while selective residues for antagonistic effects are located at the top of helices 5 and 6.
Above all, the MI analysis provides detailed indications about amino acids located in the transmembrane region of these
receptors that determine G-protein signalling pathway preferences.
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Introduction
G-protein-coupled receptors (GPCRs) constitute a large super-
family of transmembrane receptors which convey extracellular
signals into the intracellular region to effect sensory perception,
chemotaxis, neurotransmission, cell communication and several
other physiological events. The importance of GPCRs arises from
their role as signal transmitters and regulators. In humans around
850 GPCRs are known [1] and several diseases are caused by
GPCR malfunction [2–4]. They can be activated by a wide variety
of endogenous stimuli such as amino acids, peptides, ions and
(pher-) hormones [5]. GPCRs are subdivided into several families
[6], whereby the largest family is the rhodopsin-like family A.
Therefore, understanding these complex proteins and related
signaling systems is of enormous importance, not least for drug
discovery [7–11]. This is reflected by the fact that GPCRs are the
largest target group for therapeutics [12] including up to 40% of
currently marketed drugs [13].
Different structural parts of GPCRs are responsible for specific
intra- as well as intermolecular functions during a sequential signal
transduction process consisting of: i. receiving a stimulus, ii.
transmission of the stimulus by inducing conformational changes
of the receptor iii. intracellular presentation of determinants
enabling activation of signal transducers such as G-proteins [14].
Most of the endogenous and synthetic ligands of family A GPCRs
are thought to bind within the transmembrane domain close to the
second extracellular loop 2 (ECL2)[11]. Based on a huge amount of
experimental data a ‘‘global toggle switching’’ mechanism is
assumed to take place during ligand induced activation, whereby
a vertical see-saw movement of transmembrane helix (TMH) 6
occurs around a pivot [15,16]. In consequence activation is
characterized by a spatial re-arrangement of the TMHs and to
the greatest extent between TMHs 5, 6, and 7 [17,18]. This
structural re-arrangement is supported by amino acids acting as
‘‘micro-switches’’ [19,20]. In addition, contacts between ECL2 and
the extracellular extensions of the helices have been proposed to
participate as regulars during activation [21–23]. Different GPCR
conformations are related to different signalling activity states
[4,19,24] and several family A GPCR crystal structures were solved
either in the inactive [18,25–27] or the active conformation [28,29].
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guanine nucleotide-binding proteins (G-proteins), which play a
crucial role in signal transduction towards second messenger
cascades. G-protein subtypes are distinguished by their specific
alpha-subunits. The main members are termed Gas, Gaq and
Gai, whereby the induced effect on secondary messengers is
considered (e.g. s-stimulation, or i-inhibition). GPCR mediated G-
protein activation is characterized by structural shifts inside and
between the G-protein subunits, followed by exchange of GDP for
GTP in the a-subunit and separation of the Ga from the Gbc-
subunits. This opens up interfaces on the G-protein subunits to
potential contact partners such as phospho-diesterase [30]. A
detailed understanding of which structural features of GPCRs are
related to selectivity of G-protein coupling and which factors or
determinants are responsible for promiscuity in G-protein
coupling of GPCRs is not yet available. The most prominent
hypotheses addressing this topic are: 1) different conformational
states of a receptor are selective for a certain G-protein subtype,
since extracellular mutations and diverse ligands can cause
different G-protein-subtype preferences for a single receptor
[31–34]; 2) distinctive selective interaction patterns in terms of
particular intracellular residues exist, which are responsible for G-
protein subtype specific interactions [35–38]; 3) the G-protein
preference is determined by the set of cell-specific G-protein
subtype(s) [39]. None of these possibilities can be assigned as the
main cause for G-protein preference for all GPCRs. Therefore, it
is most likely that a combination of different factors define the G-
protein portfolio of a certain GPCR.
The link between the variation in receptor properties and signal
transduction specificities was studied using different theoretical
methods. Earlier studies involving information theory measures for
GPCR analysis focused on the receptor sequences and the
interrelationship of the amino acid positions. Oliveira et al. used
entropy-variability plots to detect functionally conserved residues
[40]. Ye et al. proposed a two-entropy analysis to determine the
functional positions in the transmembrane regions of GPCRs [41].
Fatakia et al. combined mutual information (MI) and concepts
from graph theory to reveal correlated positions in the major
GPCR classes [42].
The underlying study describes for the first time a chemoge-
nomics approach on the activation mechanism and G-protein
coupling of GPCRs. Chemogenomics is originally defined as a
method that discovers active and/or selective ligands for
biologically related targets in a systematic manner [43] and an
extremely broad and significant example of chemogenomics is
reported by Keiser et al. who quantitatively grouped and related
hundreds of drug targets based on the chemical similarity of
65.000 ligands [44]. For GPCRs and other target families, Jabob
and Vert proposed a more integrated chemogenomics method, as
they apply their Support Vector Machine (SVM) machine learning
algorithm to the joint chemical and the biological space, which is
an advantage as it makes targets with few known ligands benefit
from the data points of similar targets [45]. Recently, Van der
Horst et al. presented a classification of GPCRs that is purely
based on their ligands, complementing the classical sequence-
based phylogenetic classifications of these receptors [46]. Such
substructure-based and ligand-based phylogenetic classifications of
GPCRs may help to unravel potential cross-reactivities of GPCR
ligands.
The aim of this study is to identify features that link the
sequence variation of family A GPCRs and their G-protein
preference with the corresponding structural variation of agonistic
and antagonistic ligands applying the concept of mutual
information (MI). The novelty of our approach lies in the
application of the MI concept to chemogenomics of GPCRs by
including both the target sequence and ligand properties. In
contrast to previous studies, we investigated the MI between
GPCR residue variations in specific positions and the molecular
properties of ligands. Furthermore, we also analyzed such
receptor/ligand property correlations according to types of
preferred G-protein activation. Strikingly, our analyses provide
detailed indications about the effects of specific ligand properties
and the determination of G-protein preferences in the transmem-
brane domain of GPCRs.
Results
Database, GPCR alignment, ligand description and
mutual information
We gathered 100 family A GPCRs with known ligands and
information regarding their preferred G-protein subtype from the
standardized IUPHAR [47] database (figure 1a). These GPCRs cover
over 30 receptor sub-families. Several of the extracted GPCRs couple
only to a particular G-protein subtype, while most of them are able to
undergo dual G-protein coupling to Gq/Gs, Gq/Gi or Gs/Gi pairs
(figure 1b). Few receptors are known to activate all three G-protein
subtypes. We assigned agonistic and antagonistic ligands to each
receptor, whereby the individual receptor preference for G-protein
coupling was also noted. More than 1660 receptor-ligand pairs
containing 767 full agonists, 184 partial agonists and 713 antagonists
were collected (figure 1b). In order to calculate the mutual information
it is necessary to use appropriate descriptions of the sequence space and
the ligand space. The representation of the sequence space is based on
the multiple sequence alignment of the 100 analysed GPCRs using
a profile hidden Markov model. The sequence alignment is
provided under: http://fmp-berlin.info/research/structuralbiology/
researchgroups/drug-design/downloads.html. To represent the ligand
s p a c ew ec a l c u l a t e das e to fd i s c r e t ea n dc o u n t a b l em o l e c u l a r
descriptors (see section Material and Methods). The goal of mutual
information consists in finding correlations between the variation of
residues at a certain sequence position and the variation of ligand
properties. Several data sets were built in order to calculate the MI for
sequence-agonist, sequence-antago n i s t s ,s e q u e n c e - G i ,s e q u e n c e - G s
and sequence-Gq correlations. The data are shown tabulated in Table
S1.
Hot spot positions for antagonistic and agonistic effects
on GPCRs
A relatively high value for the mutual information between
receptor residue variations and ligand properties with respect to
antagonistic or agonistic ligand induced effects, lead to the
identification of common as well as selective GPCR positions.
The MI-identified hot spot positions involved in ligand induced
stabilization of the GPCR inactive state and ligand induced
receptor activation are shown in figure 2. We have mapped this
information onto the three-dimensional structure of rhodopsin for
spatial assignment of sensitive positions (figure 3a). First of all, our
analysis shows that the common family A GPCR ligand-binding
region is highly sensitive to correlated residue-ligand properties
(figure 3a,b). It is of special note that the side chains identified by
our study are mostly oriented inwards towards the transmembrane
helical bundle (figure 3a). Selective antagonistic positions are
clustered around the extracellular region, especially between
TMH5 and TMH6. Positions extracted for selective agonistic
effects in the helices are mainly located between TMH1, TMH2
and TMH3 (e.g. 1.31, 1.36; 2.40, 2.44; 3.33) compared to selective
antagonistic sensitive positions located mainly between TMH5
and TMH6 (e.g. 5.36, 5.40, 5.57).
GPCRs and Effects of Ligands on Diverse Signaling
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16811Figure 1. Extracted information from the IUPHAR database used for analyses. a) This workflow presents the methods we used to reveal the
candidates with the highest mutual information between receptor positions and ligand features. b) We gathered the GPCR information from the
IUPHAR database and extracted the 2D chemical structures from the PubChem Structure Database. In total 1664 receptor-ligand pairs were collected
for analysis, whereby 100 different family A GPCRs from 30 sub-classes with known ligands were considered. Only full agonists, partial agonists and
antagonists were explored. For the receptors their Gs, Gi and Gq coupling preferences were assigned based on the annotations in the IUPHAR
database. Several receptors are known as to be promiscuous by their capability to activate two or three G-protein subtypes.
doi:10.1371/journal.pone.0016811.g001
Figure 2. Identified positions for antagonistic and agonistic effects. This table summarizes the identified hot-spots of correlated GPCR
residue positions and specific ligand properties by separating antagonistic and agonistic effects on signaling. Details can be found in Table S1. GPCR
positions are given using the Ballesteros and Weinstein numbering [92]. For the second extracellular loop the highly conserved cysteine in ECL2,
which in most family A GPCRs is linked to the cysteine in TMH3 (position 3.25), is numbered as Lp2.50. ‘‘Lp’’ indicates that this is a loop and number 2
that it is the second loop. For visualisation different colours are used according to the assigned functional effects: green - selective for agonists; lilac -
selective for antagonist; blue - chemical descriptors of both agonists and antagonists are correlated and the number of descriptors is comparable.
Highly conserved amino acids or motifs in each helix are provided in one letter code. n - number of descriptors that are correlated significantly.
doi:10.1371/journal.pone.0016811.g002
GPCRs and Effects of Ligands on Diverse Signaling
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the highly conserved cysteine which forms a disulphide bridge with
cysteine 3.25 on TMH3) contribute significantly to ligand action,
mostly with agonistic effects.
The amino-acid side chains at several positions point towards
the membrane. These are located on the extracellular ends of
TMHs 1, 2, 5 and 7. Our analysis also reveals amino acid positions
which are most likely not involved in interactions with ligands,
especially those that are located close to the intracellular side.
Specific ligand properties can be assigned to
antagonistic and/or agonistic effects
The number of correlated ligand descriptors is in the range of 1-
16 (figure 4). High numbers of correlated descriptors might be an
indication for positions of priority in terms of ligand effect
specificity. Several descriptors are found for both types of ligands
(agonists and antagonists) but few are observable only for a
particular type of ligand-effect. Interestingly, despite occurrence of
shared descriptors to an equal amount, several of the descriptors
assigned either to agonists or to antagonists do appear with
different frequencies (high numbers versus low numbers). The
fact that similar descriptors occur with different frequencies for
the two effects could be an indication that these descriptors are
related to ligand properties causing the agonistic or antagonistic
response.
Determination of G-protein preferences encoded in the
transmembrane region of family A GPCRs
To investigate details of the general relationship between GPCR
amino acid properties, ligands and the G-protein coupling
preference we linked known G-protein (signaling pathway)
preference to each particular receptor-ligand pair. We found
three principal categories (figure 5):
1. Positions on all transmembrane helices are correlated to
ligand properties and promiscuous G-preferences for Gi, Gq and
Gs.
2. Selective amino acid positions can be found for Gs, Gq and
Gi. Interestingly, this also includes the ECL2 and helix 8. The
Figure 3. Identified positions for antagonistic and agonistic effects mapped to the rhodopsin crystal structure. a) GPCR positions
correlated with chemical properties of ligands with either antagonistic or agonistic effects are mapped onto the inactive conformation of rhodopsin
(pdb code 1U19). A colour code as in figure 2 enables the translation of functional information to the three-dimensional structure. The side-view with
rendered backbone (white) highlights spatial localization and clustering of identified positions. b) The extracellular top view shows preferred ligand
binding regions of family A GPCRs between the helices and the ECL2 close to the extracellular side. At the extracellular end especially of TMH2, 5 and
7 (boxes) several here identified amino acid side-chains are pointing towards the membrane. There involvement in ligand gating mechanisms or
structural differences between the GPCRs can be speculated. c) Scheme of hypothetical scenarios for specific ligand-receptor interaction: i) both
agonistic (green circular surface) or antagonistic effects (magenta circular surface) can be triggered at one receptor position (blue circle) dependent
to the interrelated physico-chemical ligand properties. We assume that agonistic as well as antagonistic effects might be multiplied and
simultaneously triggered at different parts of the receptor. ii) This also includes combinations between selective (triangle, trapeze) and non-selective
contact points.
doi:10.1371/journal.pone.0016811.g003
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considered are: Gi-7, Gq-14, Gs-18.
3. Correlations of amino acid positions to pairs of Gi/Gq, Gs/
Gq or Gi/Gs can be identified.
In cases 1. and 3. the number of correlated descriptor variables
can vary to a high degree (e.g. 21 vs. 4) potentially indicating the
priority of one out of two signaling pathways. This is the case for
instance at position 3.36 with Gi n=21, Gq n=8, Gs n=3, or
position 8.53 with Gi n=21, Gq n=4.
Discussion
Expansion of rhodopsin-like GPCRs started ,500 million years
ago [48]. Apart from a few exceptions such as the Glycoprotein
hormone receptors (GPHRs) and Leucine-rich repeat containing
G-protein coupled receptors (LGRs 4-8) [49], family A GPCRs are
characterized by ligand binding close to or inside the transmem-
brane helices and the extracellular loops [11,50,51]. This is in
contrast to other GPCR families and it has been proposed that this
circumstance may be the basis for their evolutionary success,
reflected by the highest number of members compared to the
more structurally complex receptor proteins that have long ligand-
binding N termini [9]. The advantages of such a ligand binding
region might be the direct link to transmembrane signal
transduction components (helices) and the general stability of the
seven transmembrane helix structure which provides a scaffold for
the evolution of new ligand binding partners. However, also for
family B GPCRs few reports pointing to a potential allosteric
ligand binding site between the transmembrane helices [52,53].
An excellent analysis of this well-known classical transmem-
brane ligand binding region, supported by various mutagenesis
studies, is given by Surgand and others for the entire collection of
non-olfactive GPCRs [11]. These authors report a clear
relationship between known ligand chemotypes (e.g. amines,
carboxylic acids, phosphates, peptides, eicosanoids and lipids) and
the cognate transmembrane cavities defined by 30 critical amino
acid positions in the transmembrane helical region. Receptors for
bulky ligands (e.g., phospholipids, prostanoids) appear to have a
transmembrane cavity significantly larger than that for smaller
compounds, and receptors for charged ligands (cationic amines,
phosphates, mono and di-carboxylic acids) always present, among
the 30 critical residues, one or more conserved amino acid
exhibiting the opposite charge.
With exceptions such as rhodopsin which has a permanently
bound inverse agonist, retinal, ligand binding is the initial event for
signal transduction through the membrane via conformational
changes in the helix arrangement [16,19,20,27,54]. Finally,
heterotrimeric G-proteins are intracellularly activated which
induces second messenger cascades [14,30,55]. Alternative signal
transducers in addition to G-proteins are also known [56].
However, signal transduction across the membrane through
GPCRs is governed by a complex set of interplaying components.
A survey of their interrelationships is important for understanding
the entire system. Several open but fundamental questions remain:
Figure 4. Frequency of descriptors for antagonists and agonists. The most significant ligand descriptors are sorted according to their
frequency of occurrence in the results of our approach. Most of them are found for both types of ligands (coloured), agonistic and antagonistic, but
few of them (white) are specifically observed only for one of each ligand-type. Interestingly, despite occurrence of descriptors for both ligand types to
an equal amount (gray), few shared descriptors are found in high or low amount for agonists or antagonists (cyan, yellow), respectively.
doi:10.1371/journal.pone.0016811.g004
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a preference either for stimulation or inhibition of the signaling
capability? Is the G-protein subtype preference of GPCRs
dependent on specific ligand properties or subsequently on
particular receptor-ligand contact positions?
The majority of the ligand-sensitive GPCR positions identified
here are located and clustered (figure 3a,b) in the well-known
transmembrane ligand binding region of family A GPCRs [57].
This includes residues in the ECL2, in agreement with a huge
amount of published GPCR data [22,58,59]. Our study shows the
ECL2 to be sensitive, especially to agonistic effects of ligands
(figure 2). We found that several positions in the family A GPCRs
investigated are correlated with both agonistic and antagonistic
ligand effects. However, we also identified positions that are
sensitive to only one effect. In this regard we would like to
highlight positions with a high number of descriptors and a strong
correlation to antagonistic signaling effects on the one hand: 2.64,
4.60, 5.36, 5.40, 6.58, 6.59, 7.33, 7.39, and a specific correlation to
agonistic signaling effects on the other hand: 1.31, 1.36, 2.60, 2.63,
3.33, Lp2.49, Lp2.51, 7.32. Supporting this, polar interactions
between amino acids in TMHs 1, 2, 3 and 7 are mandatory in
family A GPCRs in order to constrain the inactive conformation
[15,16,60,61] which might also be true for family B GPCRs [62].
Water molecules are thought to participate in this bonding-
network [63–65]. Therefore, activating effects induced by agonists
must break these constraints to enable the shift towards the active
state. In accordance with this assumption, the positions identified
here that are correlated with specific agonistic effects are indeed
located mainly in TMHs 1, 2, 3 and 7 (figure 3a,b). For the MC3R
and MC4R ligand binding and activation sensitive residues
specificly at TMHs 2, 3, 6 and TMH7 are reported [66–69]). A
further prominent example is the A2A adenosine receptor where
Jaakola and co-workers have shown that specific hydrophobic and
hydrophilic amino acid residues at TMH5 and TMH6 are
important for action of both antagonistic and agonistic molecules
[70], but they also concluded from previously published [71] and
own data that in contrast to antagonistic molecules the ribose
motif of the non-selective adenosine receptor agonist NECA binds
exclusively to residues at TMH3 and TMH7. Studies at different
GPCRs with specific ligands revealed sensitive residues for
agonistic or antagonistic effects at each helix. At the 5-
Hydroxytryptamine receptor (5HT2A) it was found, that agonistic
action is induced by ligand interactions with residues at TMH5
and TMH6 [72,73]. Furthermore, the crystal structure of the
beta2-adrenergic receptor [74] complexed with the inverse agonist
carazolol (pdb entry 2RH1) evidenced interactions (H-bonds) of
this ligand to residues at TMH3, 5, and 7. This supports the
conclusion (figure 3c) that specific combination of ligand/receptor
contacts finally determine the effect on signaling.
Several similar ligand descriptors were found to be important
for both agonists and antagonists and few of them occur with
different frequencies (figure 4). We have also depicted ligand
properties as contributing specifically to antagonistic or agonistic
effects. Therefore, our analyses suggests that both agonistic and
antagonistic effects can be triggered at the same receptor position
depending on ligand properties (figure 3c i). Additionally
combinations between non-selective and selective contacts be-
tween receptors and ligands are possible (figure 3c ii). Finally, the
amino acid positions assigned to diverse effects induced by ligands
reveal pharmacological patterns for agonists or antagonists.
It is of note that in contrast to the majority of inward pointing
side-chains identified by our study, several hot-spot residues point
out towards the membrane (figure 3a). They are located mainly at
the extracellular ends of TMHs 2, 5 and 7 (figure 3b, boxes). One
Figure 5. Receptor positions correlated with G-protein coupling preferences. In this figure the results of correlation-analysis between
receptor residue variations and properties of ligands under separation of the receptor G-protein preference(s) are summarized. The highly conserved
amino acids or motifs in each helix are provided in one letter code. The colour code highlights occurrence of single, double and also triple
preferences of certain positions for G-protein coupling (Gs, Gi, Gq): red – correlations to all three G-protein subtypes; orange – preferences for anyo f
the three possible Gq/Gs, Gi/Gs or Gi/Gq pairs; cyan – selective for Gi; magenta – selective for Gq; green – selective for Gs. n – number of descriptors
are significantly contributing to the analysed effect (Table S1).
doi:10.1371/journal.pone.0016811.g005
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structural differences between the GPCRs, because precisely these
helices are characterized by a very diverse set of helix features [75]
such as bulges and proline induced or supported kinks. These
bulges and kinks have a strong effect on the helical twist and in
consequence on the orientation of the side chains. In consequence,
we assume that these regions and amino acids might be involved in
ligand-gating mechanisms as shown in a previous study of
Hildebrand and co-workers on opsin [76]. In conclusion, the
mapping of our results for 100 different family A GPCRs onto one
structural template, the rhodopsin structure, might not be
generally representative for these particular regions. Equally,
certain structural features in the extracellular regions of the
transmembrane helices might be different for some of the family A
GPCRs, despite the high structural overlap observable in the
transmembrane region of the available GPCR crystal structures
and our results may not be completely representative. Further-
more, our method has also identified residues outside the proposed
general binding pocket region as correlated to specific ligand
properties (figure 3a). They are mainly located close to or inside
the intracellular region, which suggests their involvement in G-
protein recognition and activation. Of special note are amino acids
in helix 8. Their importance for GPCR signal transduction and G-
protein coupling was pointed out in several studies on different
GPCRs [37,77–79]. In conclusion, the identified correlations
between agonistic or antagonistic effects and positions outside the
ligand-binding region are likely related to their importance for
selective G-protein recognition or interaction with effectors.
Raymond [32] and Wess [39] have hypothesized from previous
data that certain receptor amino acids inside the transmembrane
region might be involved in the regulation of G-protein subtype
preference. In 2000 it was shown experimentally for the b2-
adrenergic receptor [33] that diverse ligands are indeed able to
induce different signaling pathways at one receptor. By using
FRET measurements on the a2-adrenergic receptor a correlation
between diverse ligands and specific receptor conformations was
recently shown [80]. Here we have found links between ligand
effects and certain GPCR amino acid positions to be correlated
with the activation of G-protein subtypes. Apart from the
observation of amino acid positions at all transmembrane helices
with correlations to effects on several G-protein subtypes (Gi, Gq,
and Gs), we also revealed residues selective for either Gs, Gq or Gi
(figures 5-6). We conclude that - comparable to the suggested
scenario for agonistic or antagonistic effects - the ligand-specific
effect on G-protein preference could be determined by the
particular contact point(s) or the combination of receptor-ligand
contacts [81,82] (figure 3c). It might be that particular structural
features on the intracellular side of the activated receptors are
involved in regulation of G-protein subtype preference
[24,32,37,39,83]. These structural features, including the intracel-
lular surface-shape, are regulated by specific ligand-receptor
contacts directing helical re-arrangements during activation. This
regulation is constituted by induction or blocking of receptor
movements. Subsequently, it would be feasible that Gs, Gi and Gq
adjust slightly differently to the receptor conformation to allow
optimal complementary intermolecular side-chain interactions in
each case. The assumption and possibility of different active
GPCR conformations, even if slight, is supported by several
published data [24,33,34,80,84].
Significance and limitations of the analyses
All findings, results and conclusions depend strongly on the
quality of the database. The standardized IUPHAR database can
be assumed to be one of the most complete collections of GPCR
ligands. The IUPHAR database also contains GPCRs with
promiscuous G-protein coupling capability (figure 2) but where
the effect of dedicated ligands is not always evidenced by
experimental studies on all types of G-protein coupling on that
particular receptor. Therefore, it cannot be excluded that some
receptor/ligand pairs assigned to a specific signaling pathway are
potentially not linked to that pathway in vivo. As an example: for
the LHCGR it was shown recently, that small allosteric ligands
that bind to and activate this receptor do not induce both signaling
pathways observed for the endogenous hormone-ligand [85].
The designated G-protein coupling (Gs, Gq, Gi) of the GPCRs
are an indirect conclusion from measurements of signaling
pathway intermediates like cAMP or calcium. The direct
GPCR/G-protein interaction is hardly ever shown or proven.
This is of relevance, because it has been discussed that the different
subunits of a G-protein subtype may not be restricted to activating
only one signaling pathway [30]. For example, for the lutropin
receptor (LHCGR) it has been suggested that the beta-gamma
subunit of Gi activates phospholipase C [86]. Therefore,
exceptions might exist from the assumed direct one to one link
between a signaling pathway and a specific G-protein subtype
(subunit).
Highly conserved residues produce low values of mutual
information and are therefore not included in the outcome of
our analysis. This does of course not exclude their potential
involvement in ligand-interaction or their participation in signal
transduction.
In summary, we conducted this analysis with a maximum of
data validation, but specific deviations from the general findings
and conclusions are to be assumed given the statistical nature of
our method and the restricted data set. A growing amount of
reliable data will lead to deeper and more detailed insights.
Taken together, our results help with respect to set of limitations
to understand GPCR signaling based on a distinct combination of
interplaying parameters constituted by the chemical-physical
properties of ligands and biophysical features of transmembrane
GPCR residues. Our results can be condensed into three main
hypotheses concerning regulation of signaling in family A GPCRs:
1. Residue positions in distinct receptor regions are specific for
antagonistic or agonistic effects induced by ligands. 2. Important
common ligand descriptors can be found for both types of ligands,
but few are unique to either antagonists or agonists and might
discriminate between the induced effects. 3. Preferences for
activation of different G-protein subtypes are causally linked to
specific residues in the transmembrane region of family A GPCRs.
Our study, therefore, provides comprehensive information for
understanding GPCR signaling and reveals new implications for
the evolutionary derived intrinsic capacities of this protein super-
family. We conducted this analysis with a maximum of data
validation, but specific deviations from the general findings and
conclusions are to be assumed given the statistical nature of our
method and the restricted data set. A growing amount of reliable
data will lead to deeper and more detailed insights.
Materials and Methods
Our analysis follows the workflow that we show in figure 1a.
After extraction of sequence-ligand pairs from the database, we
align the sequences and calculate various molecular descriptors for
the related ligands. For this data set we then calculate the mutual
information between each alignment position and each molecular
descriptor. For the significance test we repeat this calculation for
100 surrogate data sets. The top 0.5% of the mutual information
values are selected as hot spot positions.
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Annotated compound libraries have emerged as a strong
information basis for computational drug design and several
vendors provide annotated libraries for different purposes [87].
There are several open-source databases available such as the
MOAD database collected by Hu et al. [88], the GLIDA database by
Okono et al. [89] or the IUPHAR database by Harmar et al. [47].
We gathered GPCR information from the IUPHAR database [47]
and extracted the 2D chemical structures from the PubChem
Structure Database. In total we collected 1664 receptor-ligand pairs
covering 100 family A GPCRs (figure 1b). This collection
represents the maximum amount of family A GPCRs with
annotated ligands that was available from open source at the time
of our study. Only full and partial agonists/antagonists were taken
into account. Inverse agonists and allosteric modulators are not
included in this study.
Additionally the known preferences for Gs, Gi and Gq
activation which are given by the measured signalling pathway
were assigned. Several receptors are known to be promiscuous for
their ability to activate two or three G-protein subtypes (figure 1b).
The GPCR sequence alignment
The Rhodopsin-like family A GPCRs share highly conserved
residues in the seven helices [75]. Therefore the multiple sequence
alignment of the 100 analysed GPCRs (available under: http://
www.fmp-berlin.de/1129.html) is straightforward and was
achieved for the transmembrane domain with a Profile Hidden
Markov Model (HMM) as included in the HMMER software [90]
and the PF00001 profile for the rhodopsin family taken from the
Pfam database [91]. In addition, we adjusted the outcome of the
HMM by hand in order to align the second extracellular loop
(ECL2) around the cysteine residue involved in the highly
conserved disulfide bridge between ECL2 and TMH3. Manual
modifications were made to avoid gaps in the transmembrane
helices. The extracted TMHs and conserved residues were
numbered using the Ballesteros and Weinstein [92] numbering
scheme to describe the common amino acid positions.
We also modified this numbering scheme by an extension to the
extracellular (ECL) loop 2, whereby the highly conserved cysteine
in ECL2, which in most family A GPCRs interacts with the
cysteine in TMH3 (position 3.25), is numbered as Lp2.50. The
‘‘Lp’’ marks this as a loop and the ‘‘2’’ as the second loop.
Estimation of these residues into analyses is supported by several
previous studies on ligand interactions in GPCRs in the ECL2
[22].
Molecular descriptors of analysed ligands
According to Todeschini and Consonni [93], a molecular
descriptor is the ‘final result of a logical and mathematical
procedure which transforms chemical information encoded within
a symbolic representation of a molecule into a useful number or
the result of some standardized experiment’.
In order to characterize the chemical space and the properties
of the GPCR ligands we preferred discrete and countable
descriptors such as element and molecular property counts,
Ghose-Crippen AlogP [94] and electro-topological state counts
[95,96] which are easy to calculate using the two-dimensional
structural formula. The only two continuous descriptors used were
Figure 6. Receptor positions correlated with G-protein coupling preferences mapped to the rhodopsin crystal structure. a) The
amino acid positions with highly correlated mutual information to specific ligand properties (antagonists and agonists) are mapped to the structure
of rhodopsin (b, top-view), but in combination with the G-protein preference of a particular GPCR subtype indicated by specific colours according to
figure 5.
doi:10.1371/journal.pone.0016811.g006
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All molecular descriptors were calculated with the Pipeline Pilot
software (http://www.scitegic.com).
Mutual information
Mutual information is a basic concept in information theory and
provides a general measure of interdependence between random
variables.
If we consider a discrete random variable X with n possible
values taken from the alphabetAx ~ x1,x2,:::,xn fg and the associ-
ated probability distribution P(X)~fp(x1),p(x2),:::,p(xn)g then





The joined entropy H(X,Y) of two random variables X and Y










where p(xi,yj) denotes the probability of the joined occurrence of
xi and yj. The mutual information I(X,Y) between two random
variables X and Y is defined as
I(X,Y)~H(X)zH(Y){H(X,Y):
The mutual information is zero if X and Y are statistically
independent. Since it makes no assumption about the type of
relationship between X and Y, mutual information is sometimes
considered to be an extension of the linear correlation coefficient
[97].
The histogram approach is the most common way to estimate
the mutual information of a finite sample set. It calculates the
relative frequencies in the histogram bins as an estimate of the
probability distribution of the random variables.
In general the total number and the width of the bins is crucial
and has effects on the outcome of the estimation process [98]. Let
us consider K simultaneous measurements of the two random
variables X and Y with the alphabets Ax ~ x1,x2,:::,xn fg and
Ay ~ y1,y2,:::,ym fg and let kij be the total number of measure-
ments with X~xi and Y~yi. Then the probabilities p(xi,yj) are












The mutual information I(X,Y) of the two random variables X











It is known that the estimation of information theoretical
functions such as entropy and mutual information may be affected
by systematic errors. Steuer et al. pointed out [98] that the








where Mx, My and Mxy are the number of histogram bins with
nonzero probability and Kis the total number of data samples.
Estimating the Mutual Information between Sequence
Positions and Ligand Features
The random variable X is given by the distribution of the
residues in a specific alignment position whereby the 20 natural
amino acids define the canonical alphabet. The random variable Y
is given by the distribution of a specific molecular descriptor and
the alphabet is based on the discrete (countable) values. We
selected the particular subsets for agonists, antagonists and the G-
Protein coupling from the entire data set of 1664 ligand-receptor
pairs and calculated the mutual information between each
alignment position and each molecular descriptor. Only the top
0.5% of the mutual information values were selected and the
results are reported in Table S1.
Significance-Test
We formulate the null hypothesis that X and Y are independent.
To test the null hypothesis we generate 100 different surrogate
datasets XS,YS   
by creating random permutations of the
original dataset X,Y fg . We calculate the corrected mutual
information according to Equ. 1 for each surrogate realization
of the null hypothesis and estimate the mean and the standard
deviation ssur.






Under the assumption that the surrogate data follows a normal
distribution we performed a one sided t-test at an alpha=0.005
significance level which rejects the null hypothesis for S .2.63.
The values for the test statistic are reported in Table S1.
We performed a Lilliefors test in order to check the assumption
that the surrogate data sets follow a normal distribution. We test
the default null hypothesis that the data set comes from a
distribution in the normal family, against the alternative that it
does not come from a normal distribution. The test rejects the null
hypothesis at the 5% significance level in less than 10% of all cases
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